Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2023-12-04 Regulatory Filings
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva annonce la recommandation positive du troisième DMC de l’étude clinique de Phase III avec lanifibranor dans la NASH
Regulatory Filings Classification · 100% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a positive recommendation from the Data Monitoring Committee (DMC) regarding the Phase III clinical trial (NATiV3) for the drug lanifibranor. This type of announcement, detailing key clinical trial progress, safety data review outcomes, and management commentary, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a press release announcing specific clinical trial progress and safety data, it fits best under the 'Earnings Release' category (ER), which often encompasses major operational and clinical milestones announced via press release, even if not strictly quarterly financial results. It is not a full Annual Report (10-K), an Audit Report (AR), a Call Transcript (CT), or a formal Investor Presentation (IP). Given the content focuses on a major clinical update, ER is the most appropriate fit among the provided options for a significant, non-financial-statement-focused press release.
2023-12-04 French
Inventiva reports 2023 Third Quarter Financial Information¹
Earnings Release Classification · 100% confidence The document is explicitly titled "Inventiva reports 2023 Third Quarter Financial Information" and provides detailed financial results for the nine months ended September 30, 2023, including cash positions, revenues, and cash flow analysis. This content structure is characteristic of a periodic financial report covering a period shorter than a full year. The definitions provided indicate that 'Interim / Quarterly Report' (IR) is the appropriate classification for comprehensive financial reports covering periods shorter than a year (like half-year or nine-month reports). It is not an Earnings Release (ER) because it contains detailed financial tables and analysis, not just highlights. It is also not a 10-K (Annual Report). Since it is a comprehensive report, it is classified as IR. 9M 2023
2023-11-21 English
Inventiva publie ses informations financières du 3ème trimestre 2023¹
Earnings Release Classification · 99% confidence The document is titled "Inventiva publie ses informations financières du 3ème trimestre 2023" (Inventiva publishes its financial information for the 3rd quarter of 2023) and explicitly states it is publishing the financial information for the nine months ended September 30, 2023. It details key financial results (cash, revenue, operating cash flow, financing activities) and discusses clinical trial progress and future financial outlook. This content structure—a detailed report on financial performance for a period shorter than a year (nine months)—is characteristic of an Interim/Quarterly Report. The code for this is 'IR'. It is not an Earnings Release (ER) because it is a comprehensive financial update, not just the initial highlights, and it is not a full Annual Report (10-K). Since the document provides the full financial details rather than just announcing the publication of the report, it is classified as the report itself. 9M 2023
2023-11-21 French
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
Regulatory Filings Classification · 99% confidence The document is titled with an announcement: "Inventiva announces a late breaker abstract and two additional abstracts... at the AASLD The Liver Meeting® 2023". It details scientific findings, abstract titles, presentation types (Late breaker poster presentation, Poster presentation), dates, and includes standard boilerplate sections like 'About lanifibranor' and 'About Inventiva', concluding with contact information and a standard 'Important Notice' regarding forward-looking statements. This structure is characteristic of a press release announcing scientific data presentation or clinical trial updates, which falls under the general category of corporate news or regulatory announcements. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a formal voting result (DVA), the most appropriate classification is a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the slides themselves. Given it is a formal press release announcing abstract acceptance and presentation details, RNS (Regulatory Filings/General Announcement) is the best fit, as it is a broad announcement of corporate/scientific activity not covered by more specific codes like ER or CT.
2023-11-06 English
Inventiva annonce un abstract « late breaker » et deux abstracts supplémentaires sur son médicament candidat principal, lanifibranor, lors du Liver Meeting™ 2023 organisé par l’AASLD
Regulatory Filings Classification · 95% confidence The document is a press release from Inventiva announcing that abstracts related to their drug candidate, lanifibranor, have been accepted for presentation at the AASLD Liver Meeting 2023. It details the content of these abstracts (Phase II study results, correlation with adiponectin, PNPLA3 genotype independence) and provides presentation details (dates, times, poster numbers). This type of announcement, focusing on scientific data presentation at a conference, is characteristic of an Investor Presentation (IP) or a general press release about scientific progress. Since it is not a formal regulatory filing (like 10-K, AR, or ER), nor a management change (MANG) or dividend notice (DIV), and it serves to inform investors about scientific milestones and data dissemination, 'Investor Presentation' (IP) is the most fitting category, as these press releases often accompany or summarize the content of investor-facing presentations or scientific disclosures. It is not a Report Publication Announcement (RPA) because it is announcing the *content* of the data being presented, not just the publication of a formal statutory report.
2023-11-06 French
Inventiva publie ses résultats financiers du 1er semestre 2023 et fait un point sur ses activités
Interim / Quarterly Report Classification · 100% confidence The document is a press release from Inventiva titled 'Inventiva publie ses résultats financiers du 1er semestre 2023' (Inventiva publishes its H1 2023 financial results). It contains detailed financial statements (income statement, cash flow analysis) for the six-month period ending June 30, 2023, and provides a comprehensive management discussion and analysis of the company's activities, clinical trials, and financial position. As it covers a period shorter than a full fiscal year and includes substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2023
2023-09-28 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.